Positive News SentimentPositive NewsNASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $0.56 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About AEON Biopharma Stock (NASDAQ:AEON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AEON Biopharma alerts:Sign Up Key Stats Today's Range$0.55▼$0.5950-Day Range$0.56▼$1.5052-Week Range$0.55▼$17.17Volume110,702 shsAverage Volume551,287 shsMarket Capitalization$21.87 millionP/E Ratio3.11Dividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewAEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Read More… What This Post-Election Shift Means for Your Investments (Ad)The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.Click here now to watch the full briefing and prepare for what's next. AEON Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks72nd Percentile Overall ScoreAEON MarketRank™: AEON Biopharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 304th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AEON Biopharma is 3.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.76.Price to Earnings Ratio vs. SectorThe P/E ratio of AEON Biopharma is 3.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.32. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AEON. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AEON. News and Social Media3.9 / 5News SentimentN/A News SentimentAEON Biopharma has a news sentiment score of 3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AEON Biopharma this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders23.50% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AEON Stock News HeadlinesAEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comKailera Therapeutics Appoints Scott M. Akamine as Chief Legal OfficerNovember 13, 2024 | finance.yahoo.comBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, with annual revenue up nearly 100%. So why did the stock abruptly plunge following the earnings release – losing $175 billion in just 8 minutes?November 22, 2024 | Chaikin Analytics (Ad)AEON Biopharma maps FDA path for Botox biosimilarOctober 2, 2024 | investing.comBuy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue ProjectionsOctober 2, 2024 | markets.businessinsider.comAEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory MeetingOctober 1, 2024 | markets.businessinsider.comAEON Biopharma, Inc. (AEON) Stock Price, News, Quote & History - Yahoo FinanceAugust 22, 2024 | finance.yahoo.comAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024August 19, 2024 | globenewswire.comSee More Headlines AEON Stock Analysis - Frequently Asked Questions How have AEON shares performed this year? AEON Biopharma's stock was trading at $7.20 on January 1st, 2024. Since then, AEON stock has decreased by 92.2% and is now trading at $0.5590. View the best growth stocks for 2024 here. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are AEON Biopharma's major shareholders? AEON Biopharma's top institutional investors include Polar Asset Management Partners Inc. (9.20%), Geode Capital Management LLC (0.62%), Caprock Group LLC (0.16%) and HighTower Advisors LLC (0.06%). View institutional ownership trends. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AEON Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CUSIPN/A CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+794.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio3.11 Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-994.63% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.82) per share Price / Book-0.68Miscellaneous Outstanding Shares39,120,000Free Float29,928,000Market Cap$21.87 million OptionableNot Optionable Beta0.40 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:AEON) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.